Join FDLI in exploring recent regulatory developments in drug compounding. Last year, the DC District Court ruled in favor of drug compounders in Wellness Pharmacy, Inc. et al. v. Azar et al., finding that FDA’s memorandum of understanding limiting interstate distribution of compounded drugs was developed improperly and failed to assess the potential economic impact of the limitation on pharmacies. Most recently, FDA released long-awaited draft guidance on “Animal Drug Compounding from Bulk Drug Substances”. This webinar will address these updates and other important topics within drug compounding, including outsourcing facility compliance, limitations on FDA’s bulk list for compounding drug substances, and recent concerns about the safety and effectiveness of a commonly used compounded hormone therapy for women. 

Get Access

  • +$100 for nonmembers

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.


Scott Brunner , CEO, Alliance for Pharmacy Compounding 
Karla L. Palmer, Director, Hyman, Phelps & McNamara, P.C.
Ann Randall, Senior Counsel, Blue Rabbit Veterinary
Moderated by Rachael G. Pontikes, Partner, Reed Smith LLP

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.

Related Content